Advertisement

Cancer Immunology, Immunotherapy

, Volume 65, Issue 10, pp 1277–1287 | Cite as

The right patient for the right therapy: 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 11–13, 2015

  • Matthias MillerEmail author
  • Veronika Jahndel
  • Sarah Kutscher
  • Andrea Mahr
  • Richard Rae
  • Björn-Philipp Kloke
Meeting Report

Introduction

The 2015 Annual Meeting of the Association for Cancer Immunotherapy (CIMT) maintained the trend of the last CIMT meetings and with 840 participants attracted more scientists than ever before. Altogether, 77 speakers presented their data and the diverse areas of research in the field of cancer immunotherapy were discussed after the talks or in front of well over 250 posters. The overall topic was the targeted use of cutting-edge immunotherapeutic approaches by preselecting patients for a given therapy leading to the title “The right patient for the right therapy.” In this review, the highlights of the meeting are comprehensively summarized focusing on emerging trends in the field.

Personalized immunotherapy

The first session of this year’s CIMT meeting with the title “Personalized Immunotherapy” perfectly underlined the theme of the meeting. Until now, only little success has been achieved in fighting all cancers with only one drug, it has been increasingly realized that...

Keywords

CIMT 2015 Cancer immunotherapy Personalized immunotherapy Combination therapy 

Abbreviations

ACT

Adoptive cell transfer

ALL

Acute lymphoblastic leukemia

CAR

Chimeric antigen receptor

CIMT

Association for Cancer Immunotherapy

CLL

Chronic lymphocytic leukemia

CSF-1R

Colony stimulating factor 1 receptor

CTL

Cytotoxic T lymphocytes

CTLA-4

Cytotoxic T-lymphocyte-associated protein 4

CTx

Chemotherapy

DC

Dendritic cells

EMA

European Medicines Agency

EORTC

European Organization for Research and Treatment of Cancer

FDA

Food and Drug Administration

GM-CSF

Granulocyte macrophage colony-stimulation factor

HLA

Human leukocyte antigen

HMGB-1

High-mobility group box-1

HNPCC

Hereditary nonpolyposis colorectal cancer

HPV

Human papilloma virus

HSCT

Hematopoietic stem cell transplantation

IDH1

Isocitrate dehydrogenase 1

IFN

Interferon

IHC

Immuno-histochemistry

IL

Interleukin

iNOS

Inducible nitric oxide synthetase

mAb

Monoclonal antibody

MDACC

MD Anderson Cancer Center

MDSC

Myeloid-derived suppressor cells

MEK

MAP kinase kinase

MHC

Major histocompatibility complex

MMP-2

Matrix metalloproteinase-2

MMR

Mismatch repair

MSI

Microsatellite instability

mTEC

Medullary thymic epithelial cells

NGS

Next-generation sequencing

NHL

Non-Hodgkin lymphoma

OS

Overall survival

OVA

Ovalbumin

PBMC

Peripheral blood mononuclear cells

PCR

Polymerase chain reaction

PD-1

Programmed death-1

PDAC

Pancreatic ductal adenocarcinoma

PFS

Progression-free survival

RIP

Rat insulin promoter

RNA

Ribonucleic acid

SLP

Synthetic long peptide

TAM

Tumor-associated macrophages

TCGA

The Cancer Genome Atlas

TCR

T cell receptor

Teff

Effector T cell

TGF

Transforming growth factor

TIL

Tumor-infiltrating lymphocytes

TLR

Toll-like receptor

TNF

Tumor-necrosis factor

Treg

Regulatory T cells

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest. Björn-Philipp Kloke has been co-organizer of the CIMT Endeavour workshop.

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Matthias Miller
    • 1
    Email author
  • Veronika Jahndel
    • 1
  • Sarah Kutscher
    • 2
  • Andrea Mahr
    • 2
  • Richard Rae
    • 3
  • Björn-Philipp Kloke
    • 1
  1. 1.BioNTech AGMainzGermany
  2. 2.Immatics Biotechnologies GmbHTübingenGermany
  3. 3.TRON gGmbHMainzGermany

Personalised recommendations